Lexaria Bioscience Corp.

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
2.88 ^USD	-3.03%		-0.35%	+130.40%

07-17	Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study	CI
07-12	Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	CI

Lexaria Corp. will Change its Ticker to LXRP from LXRP.D

January 14, 2016 at 12:00 am

Effective January 14, 2016, Lexaria Corp. will change its Pink Sheets LLC stock ticker symbol to LXRP from LXRP.D.

Latest news about Lexaria Bioscience Corp.

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study	07-17	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	07-12	CI
HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target	07-10	MT
Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2	07-09	CI
Lexaria Bioscience Corp. Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy	07-08	CI
Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents	07-08	MT
Lexaria Bioscience Hires Contract Research Organization For 12-week Study	06-18	MT
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	06-18	CI
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	06-05	CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study	06-05	MT
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	05-21	MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	05-17	CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study	05-08	CI
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs	05-06	CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	04-16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	04-16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	04-02	CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	03-14	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	03-14	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	03-05	MT
Sector Update: Health Care	03-05	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	03-05	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	03-05	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	03-05	CI

Chart Lexaria Bioscience Corp.

Duration

Period

More charts

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.88 USD

Average target price

10 USD

Spread / Average Target

+247.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEXARIA BIOSCIENCE CORP.	+130.40%	45.53M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.22%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.53%	247B
NOVARTIS AG	+14.53%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Pharmaceuticals

Lexaria Corp. will Change its Ticker to LXRP from LXRP.D

Latest news about Lexaria Bioscience Corp.

Chart Lexaria Bioscience Corp.

Company Profile

Income Statement Evolution

Ratings for Lexaria Bioscience Corp.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals